Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
2015 · Modern Pathology · 311 citations
https://doi.org/10.1038/modpathol.2015.98
C
Carlo Garufi
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
175
Papers
4.9K
Citations
31
h-index
64
i10-index
Carlo Garufi is an academic researcher from Azienda Ospedaliera San Camillo-Forlanini. The author has contributed to research in topics: Colorectal Cancer Treatments and Studies & Cancer Treatment and Pharmacology & Gastric Cancer Management and Outcomes. The author has an h-index of 31, co-authored 149 publications.
Papers by this author
worksCetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial
2010 · British Journal of Cancer · 182 citations
https://doi.org/10.1038/sj.bjc.6605940
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
2020 · Journal of Experimental & Clinical Cancer Research · 72 citations
https://doi.org/10.1186/s13046-020-01797-3
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
2021 · Scientific Reports · 43 citations
https://doi.org/10.1038/s41598-021-92774-z
Gender effects of single nucleotide polymorphisms and miRNAs targeting clock-genes in metastatic colorectal cancer patients (mCRC)
2016 · Scientific Reports · 24 citations
https://doi.org/10.1038/srep34006
A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients
2003 · British Journal of Cancer · 22 citations
https://doi.org/10.1038/sj.bjc.6601382
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat